GKOS GLAUKOS Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development, manufacturing, and commercialization of ophthalmic surgical implants and pharmaceutical therapies
• • New product emphasis: Commercial launch of iDose TR implant in early 2024 and FDA approval plus planned commercialization of Epioxa pharmaceutical therapy in early 2026
• • Strategic risk exposure: Increased vulnerability to geopolitical conflicts, economic volatility, and supply chain disruptions impacting manufacturing and regulatory processes
• • Quantitative metric: Accumulated deficit of approximately $933.1 million as of December 31, 2025 reflecting ongoing investment and operating losses
• • Noteworthy fact: First-time FDA approval of Epioxa in October 2025, an incision-free keratoconus treatment alternative, marking significant product portfolio expansion

Risk Factors

• • Regulatory risk: U.S. FDA approval of Epioxa in October 2025 requires securing permanent HCPCS J-Code and commercial payer coverage for reimbursement
• • Macroeconomic risk: U.S. tariffs on imports from Canada, Mexico, and China, despite limited exposure, risk escalating trade disputes affecting sourcing costs
• • Supply chain risk: Vendor supply shortages and labor disruptions causing longer lead times and higher raw material costs, impacting gross margins and product availability
• • Competitive risk: Royalty income from Ivantis’ Hydrus Microstent expired April 2025, coinciding with competitor Alcon’s acquisition of Ivantis
• • Financial risk: Accumulated deficit of $933.1 million as of December 31, 2025 with net losses of $187.7 million in 2025, reflecting ongoing unprofitability and high operating expenses

Management Discussion & Analysis

• • Revenue $507.4M, up 32% YoY from $383.5M; US glaucoma sales up 50% to $298.6M, international glaucoma up 18% to $122.5M
• • Gross margin 56% in 2025 vs 75% in 2024; Operating loss $(199.6)M vs $(122.4)M; Net loss $(187.7)M vs $(146.4)M
• • Best segment US glaucoma sales $298.6M (+50%); Worst margin impacted by $112.9M intangible asset impairment, driving cost of sales 139% higher to $224.7M
• • Cash/cash equivalents $90.8M; short-term investments $187.9M; operating cash used $14.8M; investing cash used $77.6M; financing cash provided $11.9M; $80M+ capex planned for Huntsville facility
• • Management expects higher 2026 capex with Huntsville facility construction; key risk in funding operations as cash flows and profitability remain negative

What are the latest GKOS SEC filings in 2026?

GLAUKOS Corp (GKOS) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did GKOS file its most recent 10-K annual report?

GLAUKOS Corp (GKOS) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view GKOS 10-Q quarterly reports?

GLAUKOS Corp (GKOS)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every GKOS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has GKOS filed recently?

GLAUKOS Corp (GKOS)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find GKOS insider trading activity (Form 4)?

SignalX aggregates every GKOS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does GKOS file with the SEC?

GLAUKOS Corp (GKOS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GKOS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for GLAUKOS Corp (GKOS).

What is GKOS's SEC CIK number?

GLAUKOS Corp (GKOS)'s SEC CIK (Central Index Key) number is 1192448. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1192448 to look up all GKOS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find GKOS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from GLAUKOS Corp (GKOS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.